COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01829061
Recruitment Status : Terminated (Data for Study Devices vs. Predicate not within allowable ranges.)
First Posted : April 11, 2013
Last Update Posted : March 29, 2016
Information provided by (Responsible Party):
Quotient Diagnostics Limited

Brief Summary:
The Quo-Test A1C Analyzer and Reagent Test System (Quo-Test A1C System) are intended for the in-vitro quantitative determination of glycated hemoglobin in whole blood samples obtained from fingerstick or venous samples for point-of-care testing. The Quo-Test A1C System is indicated in the management and treatment of diabetes and for monitoring long term glycemic control by diabetics. It is for multiple patient use. Only auto-disabling, single use lancing devices should be used with this system.

Condition or disease

Layout table for study information
Study Type : Observational
Actual Enrollment : 360 participants
Official Title: Reproducibility and Method Comparison of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver of the Quo-Test™ A1C System
Study Start Date : April 2013
Actual Primary Completion Date : January 2014
Actual Study Completion Date : April 2014

No Treatment

Primary Outcome Measures :
  1. The objective is to conduct reproducibility testing using duplicates of each of 3 levels of HbA1C [ Time Frame: 10 Days ]
    The objective is to conduct a method comparison between both the Quo-Test and Quo-Lab investigational devices and the reference method [Tosoh G8 (K071132)]. The reference method also serves as the predicate for the premarket notifications for both investigational devices. Both capillary and venous samples will be tested on the Quo-Test A1C System and Quo-Lab A1C Test, while only venous samples will be tested on the reference method.

Secondary Outcome Measures :
  1. Obtain CLIA Waiver Status for the Quo-Test [ Time Frame: 10 Days ]

Biospecimen Retention:   Samples Without DNA
Whole Blood Venous Draw and Capillary Blood - IVD Study

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
From site's patient database

Inclusion Criteria:

  • Aged 18 years or over
  • Able to read English
  • Read, understood and signed the Informed Consent Form
  • Agrees to participate and does not withdraw\
  • Either healthy (without diabetes) or has Type 1 or Type 2 diabetes

Exlcusion Criteria:

• Declines participation or withdraws before study completion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01829061

Layout table for location information
United States, California
AMCR Institute
Escondido, California, United States, 92026
United States, Minnesota
Ridgeview Research
Chaska, Minnesota, United States, 55318
United States, Missouri
University of Missouri
Columbia, Missouri, United States, 65212
Sponsors and Collaborators
Quotient Diagnostics Limited
Layout table for investigator information
Principal Investigator: Tim Bailey, MD AMCR Institute
Principal Investigator: Stephanie Svoboda, PharmD Ridgeview Research
Principal Investigator: Michael Gardner, MD University of Missouri-Columbia
Layout table for additonal information
Responsible Party: Quotient Diagnostics Limited Identifier: NCT01829061    
Other Study ID Numbers: QDL Clinical Studies
First Posted: April 11, 2013    Key Record Dates
Last Update Posted: March 29, 2016
Last Verified: November 2013
Keywords provided by Quotient Diagnostics Limited:
Type I Diabetes
Type II Diabetes